Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00005592 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: 90-Y-ibritumomab tiuxetan
BIOLOGICAL: rituximab
RADIATION: indium In 111 ibritumomab tiuxetan

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]
[object Object]